No images? Click here Alopecia Areata Language in Omnibus BillRepresentative Ayanna Pressley (center) with NAAF Legislative Liaisons in Washington, DC. The recently passed congressional Omnibus FY 2023 Appropriations bill includes the following language created by by Representative Ayanna Pressley (D-MA): Alopecia Areata.—The Committee notes the importance of research into autoimmune skin conditions such as alopecia areata. The Committee requests an update in the fiscal year 2024 Congressional Justification on research initiatives into this condition and opportunities to advance research. Mental Health Impact of Alopecia.—The Committee notes recent events that have highlighted the effect on an individual’s mental health because of alopecia. The Committee encourages the National Institutes of Mental Health (NIMH) to work with key stakeholders to advance research and resource development aimed at understanding this connection and opportunities for innovative discovery. Racial and Ethnic Disparities in Alopecia.—The Committee notes the disproportionate effect of alopecia on people of color, specifically women. The Committee encourages National Institutes of Minority Health and Health Disparities (NIMHD) to collaborate with relevant Institutes and Centers, such as the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), and relevant stakeholders to identify key research areas of concern. The included language is important as it demonstrates Congress is not only serious about finding new treatments and a cure for alopecia areata, but learning more about the mental health impact the disease has, and its disproportionate effect on minority communities. The language also reinforces the argument that alopecia areata is not simply a cosmetic condition but a serious autoimmune disease worthy of insurance coverage for wigs and treatments. Treatment Development Program Impact Report Read how NAAF’s Treatment Development Program played a significant a 12-year role in the research, breakthroughs, and clinical trials that led to the first-ever FDA-approved treatment for alopecia areata. It’s all here in the 2022 Treatment Development Program Impact Report. NAAF Awards Two Grants NAAF is pleased to announce that it has awarded two grants to further research into alopecia areata in children and adolescents. Each recipient of the Pediatric Alopecia Areata Challenge Grant will receive $50,000 for a 12-month investigation. NAAF partnered with the Pediatric Dermatology Research Alliance (PeDRA) to launch the Challenge Grant. Fundraiser a Rockin’ SuccessGuitar-slinging Mia Miller and her parents, Reed and Jill, held a hugely successful fundraiser for NAAF by selling t-shirts with a graphic of Mia shredding on her axe with the logo “You can rock alopecia. And…you’re awesome!” Dubbed the “Awesome Alopecia Rocker” by local TV show, Living Well, Mia and her fundraiser brought in $10,000 in donations. You can do the same! Just find what you love and do it for NAAF. Contact us at info@naaf.org to learn more. And watch Mia’s Living Well appearance Here>>. Next Webinar: Patient Guide to Clinical Trials and Drug Development Danielle Quarles NAAF is hosting its next live webinar, Patient Guide to Clinical Trials and Drug Development: Phases and Terminology Explained! on Wednesday February 15th at 7:00pm ET/ 6:00pm CT/ 4:00pm PT. Have you read announcements for clinical trials but don’t quite understand what they mean? Do you want to feel comfortable advocating for yourself when discussing clinical trial options with your doctor? Join us to learn about drug development including how clinical trials are planned, the phases they go through, and the role that patients play in clinical trial conduct. We will cover questions to ask your doctor, things to consider when evaluating whether to participate in a trial, and how your participation could move alopecia areata treatments closer to FDA approval. This presentation will focus on clinical trials for adults. Speaker Danielle Quarles has 20 years of experience in clinical research and drug development. She is a senior director of clinical operations in the biotech industry and has two children with alopecia areata. This webinar is part of NAAF’s You Are Not Alone: Education and Empowerment Webinar Series. NAAF gratefully acknowledges support for this webinar series from Eli Lilly and Company. 2023 Student Internship Awards
|